Stock comparison
Moderna, Inc. is 2.2x more valuable than BioNTech SE by market capitalization ($57.75 B vs $26.24 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 2.2x more valuable than BioNTech SE by market capitalization ($57.75 B vs $26.24 B).
Market value leader
MRNA
Moderna, Inc. is 2.2x more valuable than BioNTech SE by market capitalization ($57.75 B vs $26.24 B).
| Metric | MRNA | BNTX |
|---|---|---|
| Market cap | $57.75 B | $26.24 B |
| US-listed rank | #290 | #514 |
| Revenue (latest FY) | $1.94B | - |
| Net income (latest FY) | -$2.82B | - |
| Net margin | -145.2% | - |
| P/E (trailing FY) | - | - |
| SEC filings | 1,447 | 548 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 2.2x more valuable than BioNTech SE by market capitalization ($57.75 B vs $26.24 B).
Full pages: Moderna, Inc. and BioNTech SE, or browse the full rankings.